Crystallization Process Development

Scalable, QbD-Driven Process Engineering

Transforming a newly discovered crystal form into a scalable manufacturing process requires a blend of deep theoretical understanding and strict process control. We design processes that consistently yield your target crystal form while optimizing API particle properties, overall yield, and production costs.

Optimization & Risk Control

Quality by Design (QbD)

Implementing rigorous QbD principles to ensure manufacturing robustness and predictable product quality.

Parameter Analysis

Analyzing key process parameters to understand their impact on the final crystal form and particle attributes.

Design Space Determination

Defining the acceptable design space and establishing optimal operating ranges for consistent production.

Risk Control Strategies

Creating robust risk control strategies to mitigate variability during commercial-scale manufacturing.

Advanced Form Control

Metastable Polymorph Expertise

Expertly managing complex crystallization systems to deliver target forms that are naturally prone to transformation.

Transformation Control

Developing specialized strategies to prevent metastable forms from naturally transforming into more thermodynamically stable states during scale-up.

Precision Scaling

Our comprehensive platform ensures the precise delivery of your target form at scale, regardless of system complexity.

Thermodynamic Mastery

Utilizing deep theoretical insights to expertly navigate the boundaries between different polymorphic states.

Related Platforms of Crystal Pharmatech

Solid Form Screening



Solid Form Developability Evaluation



Absolute Structure Determination



Related Resources

News

Crystal Pharmatech Launches OEB4/OEB5 High-Potency Laboratory, Expanding Global CDMO Capabilities for Complex Drug Development

02 Apr 2026



Technical Article

Bilayer Gastroretentive Modified-Release Tablets: A Quality-by-Design Approach to Achieving Precise Drug Release and Prolonged Gastric Retention

01 Apr 2026



News

Patients can’t carry a fridge around: research meets the real world

20 Mar 2026



Small Molecule

First-Time-Right 3-STEP Approach Developability Assessment API Form and Solid-State Research Crystallization Development Services Pre-formulation Studies Analytical Research and Quality Control Formulation Development Clinical and Commercial GMP Manufacturing Clinical Supply

Crystal Bio Solutions

Biologics Characterization and CMC Analytics Bioanalytical and Biomarker Services Quantitative Clinical Pharmacology (QCP)

Crystal NAX

DNA Synthesis RNA Synthesis LNP Formulation Services Analytical & Characterization Services Early-Phase Manufacturing Catalogue Products

Platforms

Solid Form Screening Solid Form Developability Evaluation Absolute Structure Determination Crystallization Process Development Conventional Oral Solid Dosage Forms Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides Mini-tablet

Quick Links

Highlights News Events Knowledge Hub Webinar Series

 bd_global@crystalpharmatech.com  (925) 558-5040



U.S
NJ Sites: Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey, USA 08512

2005 Eastpark Blvd, Cranbury, New Jersey, USA 08512

CA Site: 7133 Koll Center Parkway, Suite 200, Pleasanton, California, USA 94566

Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1

China
No. 288, Jiangyun Road, Suzhou Industrial Park, Suzhou, China 215123

Floor 1, Bldg. 3, 68 Chunpu Road, Suzhou Industrial Park, Suzhou, China 215123

Subscribe to be the first to get the updates!

Sitemap